Cancer
Cancer Ongoing 2021 Cabrini VIC

MASTERPLAN

This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.

Trial overview

Disease
MASTERPLAN
Topic
MASTERPLAN
Description
MASTERPLAN: A randomised phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease.
Eligibility criteria
  • Adults, aged between 18-75 years 
  • histologic confirmation of pancreatic adenocarcinoma 
  •  Any of the following: 
    • T3 (tumour >4 cm)
    • Extrapancreaticextension 
    • Node positive (Stage IIB)
    • Borderlineresectablepancreatic cancer or 
    • Locally advanced pancreatic cancer
  • ECOG 0-1 
  • Tumour size <70mm 
  • No evidence of metastasis 
Study details

Arm A: Control (40 patients): Standard of care chemotherapy.

Arm B: Investigational (80 patients): Standard of care chemotherapy with the addition of SBRT.

Further information

For more information regarding this clinical trial click here.

Location

Cabrini VIC